The investment firm Blackstone is scooping up a majority stake in the direct-to-consumer genetics company Ancestry for $4.7 billion. | Continue reading
The coronavirus is an easier target for potential vaccines than other pathogens, and a prime candidate for new cutting-edge vaccine platforms. | Continue reading
Two new studies suggest the possibility of long-term damage after people recover from Covid-19, even if it was not severe enough to require hospitalization. | Continue reading
We need to reduce the cost of producing physicians, not just the price of medical school, to make the profession more accessible to all. | Continue reading
The growing number of people with post-Covid syndrome is prompting researchers to look to chronic fatigue syndrome (ME/CFS) for clues. | Continue reading
A growing number of prominent hospitals are using AI-powered tools to advise patient care. But patients often aren't informed, a STAT examination finds. | Continue reading
Doctors and medical students have warned for years that a common kidney test is racist and dangerously inaccurate. Their appeals are gaining new traction. | Continue reading
Synthetic biology and fermentation offer a promising alternative to traditional manufacturing for fixing the broken supply chain for drug ingredients. | Continue reading
STAT asked a number of public health experts for a single suggestion of how we get ourselves out of this mess. We got lots. | Continue reading
A new STAT analysis shows the effort to study treatments has been marked by disorder and chaos, with huge financial resources wasted. | Continue reading
Researchers reported Wednesday that they had turned a bacterial toxin into the world’s first editor of genes in mitochondria, the cell's power plant. | Continue reading
More than $100 billion in NIH funding went toward research that contributed, either directly or indirectly, to the the drugs, which were approved between 2010 and 2016. | Continue reading
The U.S. sued Regeneron for making "kickbacks." That's wrong. It donated money to a nonprofit foundation to help patients pay for an expensive eye drug. | Continue reading
The warning from the head of the National Institute of Allergy and Infectious Diseases came as the number of new cases hovering around 40,000 per day. | Continue reading
When Covid-19 hits the brain, it can cause strokes, psychosis, and dementia-like syndrome, per a new survey of patients with the condition. | Continue reading
As Covid-19 cases spike in Oklahoma, President Trump is holding an indoor rally in Tulsa. It violates all of the CDC's rules for safety. | Continue reading
If the U.S. had moved as quickly as other countries at the start of the pandemic, between 70% and 99% of Covid-19 deaths might have been prevented. | Continue reading
The landmark deal with the world's second largest academic publisher, Springer Nature, could get more journal articles out in front of paywalls. | Continue reading
After strong pushback, a top WHO official clarified scientists don’t know yet how often asymptomatic Covid-19 patients are spreading the disease to others. | Continue reading
In the past two years, the Mayo Clinic has provided de-identified patient data to 16 digital companies eager to create health AI products and services. | Continue reading
In a secret experiment, researchers replaced the dysfunctional brain cells of a Parkinson’s patient with the progeny of an extraordinary type of stem cell. | Continue reading
The journal said the authors of the paper about hydroxychloroquine were unable to complete an independent audit of the data underpinning their analysis. | Continue reading
Despite a lack of evidence, many people began taking the medicine to try to prevent infection early in the Covid-19 pandemic. | Continue reading
With a global pandemic and a fraught trade war, many are wondering if China’s pharmaceutical monopoly presents a national security threat. | Continue reading
In hospitals, profitable procedures subsidize the unprofitable care, and it sort of works out in the end. Except during a viral pandemic. | Continue reading
The last major outbreak of bubonic plague started on May 25, 1720, in Marseille, France. The response to it was a lot like the U.S.'s response to Covid-19. | Continue reading
A deep dive into how the new coronavirus infects cells has found that it orchestrates a hostile takeover of their genes unlike any other known viruses do. | Continue reading
While Moderna blitzed the media, it revealed very little information — and most of what it did disclose were words, not data. | Continue reading
STAT spoke to leading health care thinkers about how the coronavirus has shattered long-standing assumptions about health policy in the U.S. | Continue reading
President Barack Obama and his science advisers developed a playbook for confronting a future pandemic. President Donald Trump ignored it — and science. | Continue reading
Gilead Sciences is going all in on its antiviral drug remdesivir. It should also be testing its older drug, GS-441524. It works the same way, only better. | Continue reading
Amazon is sharing its staff's expertise with scientists across the country — and digging into its deep pockets to fund a smattering of Covid-19 studies. | Continue reading
Reopening the economy will involve coronavirus-testing programs and contact tracing similar to those used in the adult film industry for HIV. | Continue reading
Physicians around the country criticized the federal government for the uneven and opaque way it is distributing its supply of the Covid-19 drug remdesivir. | Continue reading
Gilead said it is pursuing several steps to ensure global access to remdesivir for Covid-19 patients, including licensing agreements to supply the drug to countries beyond the U.S. | Continue reading
I've met these patients in a starkly different way than I would have during face-to-face encounters in the emergency department. | Continue reading
The idea of controlled human infection trials has been met with enthusiasm in some quarters, and reservations in others, including from some who run them. | Continue reading
Some scholars and academics wrongly ascribe scientists' legitimate disagreements about Covid-19 to ignorance or questionable political or other motivations. | Continue reading
Drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. Here's your guide to drugs and vaccines in development. | Continue reading
The analysis shows the U.S. is at risk of fumbling the next challenge: testing enough people to determine which cities and states can safely reopen. | Continue reading
Doctors treating the sickest Covid-19 patients have zeroed in on a new phenomenon: Some people have developed widespread blood clots. | Continue reading
Our inability to start and run clinical trials faster — whether in a pandemic or not — is a legacy of our decision not to develop the right technologies. | Continue reading
The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients in China with Covid-19 or prevent them from dying. | Continue reading
Explore our Covid-19 Preparedness Scores map to learn how prepared your county is for an outbreak. Learn more. | Continue reading
Epidemiologists are criticizing an influential coronavirus model as flawed and warning against relying on it as the basis for government decision-making. | Continue reading
The idea to begin testing wastewater for SARS-CoV-2 emerged after recent research revealed that virus particles could be shed through stool. | Continue reading
Former director Tom Frieden said that the CDC has served a vital role during the pandemic and that top officials there tried to sound the alarm early. | Continue reading
The idea to begin testing wastewater for SARS-CoV-2 emerged after recent research revealed that virus particles could be shed through stool. | Continue reading